Form 990 for tax year 2023
Filed by NATIONAL ATAXIA FOUNDATION INC.
Totals
- Total revenue
- $3,981,625
- Total expenses
- $4,863,570
- Contributions and grants received
- $3,083,219
- Grants paid
- $1,749,340
- Program service revenue
- $835,649
- Investment income
- $73,728
- Other revenue
- -$10,971
- Total assets, end of year
- $4,116,826
- Total liabilities, end of year
- $501,880
- Net assets or fund balances, end of year
- $3,614,946
- Program services expenses (Part IX)
- $3,787,844
- Management and general expenses
- $538,078
- Fundraising expenses
- $537,648
- Program service expenses (Part III)
- $3,787,844
Program services were 77.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1c · Fundraising events
$238,837
-
1f · All other contributions, gifts and grants
$2,844,382
-
2a · Program service revenue: Drug Development Colla
total $570,833 · related or exempt $570,833
-
2b · Program service revenue: Conference income
total $264,816 · related or exempt $264,816
-
3 · Investment income
total $73,728 · excluded $73,728
-
8a · Fundraising events: gross income
$0
-
8a · Fundraising events: contributions included on line 1c
$238,837
-
8b · Fundraising events: direct expenses
$10,971
-
8c · Net income from fundraising events
total -$10,971 · excluded -$10,971
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $1,318,020 · program services $1,318,020
-
2 · Grants to domestic individuals
total $26,520 · program services $26,520
-
3 · Grants to foreign organizations and individuals
total $404,800 · program services $404,800
-
5 · Compensation of officers, directors and key employees
total $553,270 · program services $387,299 · management and general $53,417 · fundraising $112,554
-
7 · Other salaries and wages
total $922,520 · program services $648,075 · management and general $87,822 · fundraising $186,623
-
9 · Other employee benefits
total $146,488 · program services $94,943 · management and general $18,271 · fundraising $33,274
-
10 · Payroll taxes
total $109,128 · program services $77,686 · management and general $9,732 · fundraising $21,710
-
11a · Fees: management
total $91,671 · program services $43,151 · management and general $38,198 · fundraising $10,322
-
11b · Fees: legal
total $5,640 · program services $5,640
-
11c · Fees: accounting
total $15,605 · management and general $15,605
-
11g · Fees: other
total $111,339 · program services $52,409 · management and general $46,393 · fundraising $12,537
-
12 · Advertising and promotion
total $87,615 · program services $11,925 · management and general $45,852 · fundraising $29,838
-
13 · Office expenses
total $51,076 · program services $8,889 · management and general $31,985 · fundraising $10,202
-
16 · Occupancy
total $63,895 · management and general $63,895
-
19 · Conferences, conventions and meetings
total $804,642 · program services $690,799 · management and general $44,865 · fundraising $68,978
-
23 · Insurance
total $12,931 · management and general $12,931
-
24a · Other expenses: Dues and subscriptions
total $80,410 · program services $8,106 · management and general $22,422 · fundraising $49,882
-
24b · Other expenses: Bank and credit card fe
total $48,615 · program services $4,924 · management and general $43,691
-
24c · Other expenses: Miscellaneous
total $5,008 · program services $3,640 · management and general $140 · fundraising $1,228
-
24d · Other expenses: Professional developmen
total $4,377 · program services $1,018 · management and general $2,859 · fundraising $500
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $1,969,164 · end of year $550,112
-
2 · Savings and temporary cash investments
beginning of year $1,642,051 · end of year $468,613
-
4 · Accounts receivable
beginning of year $55,331 · end of year $6,438
-
9 · Prepaid expenses and deferred charges
beginning of year $187,070 · end of year $255,729
-
11 · Investments: publicly traded securities
beginning of year $1,065,945 · end of year $2,778,614
-
15 · Other assets
beginning of year $89,034 · end of year $57,320
-
17 · Accounts payable and accrued expenses
beginning of year $470,035 · end of year $333,967
-
19 · Deferred revenue
beginning of year $22,291 · end of year $109,810
-
25 · Other liabilities
beginning of year $89,652 · end of year $58,103
-
27 · Net assets without donor restrictions
beginning of year $2,404,811 · end of year $934,379
-
28 · Net assets with donor restrictions
beginning of year $2,021,806 · end of year $2,680,567
Mission and programs · 2023
Mission
The National Ataxia Foundation's mission is to accelerate the development of treatments and a cure while working to improve the lives of those living with Ataxia.
Activities or mission (Part I)
To accelerate the development of treatments and a cure while working to improve the lives of those living with Ataxia.
-
The National Ataxia Foundation offers patient education, advocacy, and support programs to improve the lives of those living with Ataxia. NAF's patient education program provides an annual conference, webinars, and fact sheets to help individuals manage their health and quality of life. NAF's advocacy program involves policy makers and pharmaceutical companies to grow awareness of Ataxia, accelerate drug development and ensure access to care and treatment services. NAF's support group program offers a way for the Ataxia community to connect and learn from others.
Expenses $1,037,255 · Grants $26,520 · Revenue $264,816
-
NAF is committed to funding cutting-edge basic and translational research into hereditary and sporadic ataxia. The goals of NAF's research program are to further elucidate the disease mechanisms of ataxias, bring early-career clinicians and scientists into ataxia research, and help drive the field towards developing treatments and a cure for ataxia. Annual grants are selected through a competitive review process that includes NAF's Medical and Research Advisory Board members and over 80 leading ataxia scientists and clinicians, both domestic and international. Each year NAF awards grants to researchers from domestic and international non-profit and for-profit institutions that directly support basic and translational ataxia research through the following funding mechanisms:1. Pioneer SCA3 Translational Research Awards: Annually granted to outstanding research proposals that aim to make significant advancements in the development of treatments and/or improvements to patient care for Spinocerebellar Ataxia Type 3 (SCA3). Proposals may incorporate other forms of ataxia but must have a predominant focus on SCA3 translational or clinical research. 2. Seed Money Research Grant: Granted primarily as "seed monies" to assist investigators in the early or pilot phase of their studies and as additional support for ongoing investigations on demonstration of need. It is hoped that these studies will be further developed to attract future funding from other sources. 3. Post-doctoral Fellowship Award: Post-doctoral fellowship awards are to serve as a bridge from post-doctoral positions to junior faculty positions. Applicants should have completed at least one year of post-doctoral training, but not more than two at the time of application and should have shown a commitment to research in the field of ataxia. The award will permit individuals to spend an additional third year in a post-doctoral position and increase chances to establish an independent ataxia research program.4. Early Career Investigator Award: The Early Career Investigator Award was created to encourage early career clinical and scientific investigators to pursue a career in the field of ataxia research. 5. Pre-doctoral Fellowship to Promote Diversity in Ataxia Research: Merit-based award intended to enhance research and/or clinical training of promising graduate students from historically underrepresented backgrounds who are matriculated in pre-doctoral or clinical health professional degree training programs and who intend careers as scientists or other clinician-scientists within the field of ataxia. 6. National Ataxia Foundation Graduate Research Fellowship: The National Ataxia Foundation Graduate Research Fellowship is a competitive, non-renewable, merit-based award intended to encourage pre-doctoral students to pursue research and a career in the field of ataxia. 7. NAF Special Grants: Based on the emergent needs of the patient and research community, priority areas of ataxia research may be identified as eligible for specialized grant funding by NAF and may be awarded outside of the annual grant programs. In addition to NAF annual grants, NAF sponsors several clinical research programs that aim to drive advancements in the ataxia research field and prepare the ataxia community for future clinical trials. One of these programs is the Ataxia Tissue and Brain Donation Program. NAF and the University of Florida's Center for NeuroGenetics (CNG) work together to maintain a repository of brain and spinal cord tissue from ataxia donors. This tissue is available to SCA researchers to help advance our understanding of these diseases and to develop new therapies. NAF sponsors both the costs of tissue donation and maintenance costs of the brain and tissue bank.
Expenses $1,562,162 · Grants $740,530
-
Funding for several of NAF's other key clinical research programs are provided through the NAF Drug Development Collaborative (DDC). The DDC is a pre-competitive pharmaceutical industry consortium with a principal goal of accelerating the development of treatments for ataxia. The Collaborative provides a centralized source for access to resources needed to support research and development of Ataxia therapies. Specific objectives of the Collaborative include natural history and bio sample data collection, development of biomarkers, validation of rating scales, clinical trial design, patient-reported outcomes, and other data necessary for the development and approval of safe and effective therapies. Two significant programs that are largely sponsored by the DDC include:1. No-cost Genetic Counseling and Testing Initiative: This program provides virtual genetic counseling and testing for individuals at-risk for three of the most common dominant ataxias to members at no-cost to participants. The aim of this program is to help individuals overcome barriers that have historically inhibited wide-spread genetic testing as well as support drug development through expanding the patient population eligible for future clinical trials.2. Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) Natural History Study: The CRC-SCA is one of the longest running and largest natural history studies of spinocerebellar ataxias (SCAs). A natural history study collects data that shows how a specific disease progresses in individuals over time. Natural history studies are essential for developing clinical trial designs that will facilitate drug development. There are over 300 patients enrolled at 16 CRC-SCA sites in the US and Canada. During annual visits, site investigators collect critical clinical data to aid in understanding disease progression and help guide future clinical trial design. Biofluids, such as plasma, serum, and cerebrospinal fluid, are also collected from patients and stored at the NINDS SCA-BRAC biorepository. Both deidentified clinical data and biofluids are available for request from non-participating investigators for approved research projects.
Expenses $1,188,427 · Grants $982,290 · Revenue $570,833
As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Samuel Kirton
President
- Total calculated
- $0
- Hours/week
- 5
-
Linda Snider
Vice President
- Total calculated
- $0
- Hours/week
- 2
-
Greg Rooks
Treasurer
- Total calculated
- $0
- Hours/week
- 2
-
John Mauro
Secretary
- Total calculated
- $0
- Hours/week
- 2
-
David Brunnert
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Cindy DeMint
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Michael Cammer
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Jim Keene
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Greg Klassen
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Ann Riley
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Denise Kolpack
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
John Dwyer
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Serena Hung
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Hayley McLoughlin
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
David Spotts
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Mark Hazlin
Board Member
- Total calculated
- $0
- Hours/week
- 2
-
Andrew Rosen
Chief Executive Officer
- Total calculated
- $199,072
- From this org
- $186,696
- From related orgs
- $0
- Other
- $12,376
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $186,696
- Bonus
- $0
- Other
- $0
- Deferred
- $8,654
- Nontaxable benefits
- $3,722
- Filer's total
- $199,072
-
Joel Sutherland
VP of Development
- Total calculated
- $159,390
- From this org
- $151,534
- From related orgs
- $0
- Other
- $7,856
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $151,534
- Bonus
- $0
- Other
- $0
- Deferred
- $2,260
- Nontaxable benefits
- $5,596
- Filer's total
- $159,390
-
Lauren Moore
VP and Chief Scientific Officer
- Total calculated
- $194,809
- From this org
- $189,726
- From related orgs
- $0
- Other
- $5,083
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $189,726
- Bonus
- $0
- Other
- $0
- Deferred
- $3,180
- Nontaxable benefits
- $1,903
- Filer's total
- $194,809
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 2 · Substantiation required before reimbursing expenses
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
Research
-
University of Texas Southwestern
$147,450
Research
-
University of South Florida
$106,117
Research
-
Research
-
Massachusetts General Hospital
$89,400
Research
-
$70,550
Research
-
Research
-
Research
-
$50,000
Research
-
Duke University Medical Center
$50,000
Research
The 10 largest by cash amount. The API serves every itemized grant.
Fundraising and gaming
From Schedule G of this return, as filed.
- Had an agreement with a professional fundraiser (line 2a)
- Not answered
Fundraising events (Part II)
Part II has at most four columns: the two largest events, the rest together, and the total.
| Line | Event 1 Walk n Roll | Total |
|---|---|---|
| Gross receipts (line 1) | $238,837 | $238,837 |
| Less contributions (line 2) | $238,837 | $238,837 |
| Gross income (line 3) | — | — |
| Cash prizes (line 4) | — | — |
| Noncash prizes (line 5) | — | — |
| Rent and facility costs (line 6) | $10,836 | $10,836 |
| Food and beverages (line 7) | — | — |
| Entertainment (line 8) | — | — |
| Other direct expenses (line 9) | $135 | $135 |
- Direct expenses (line 10)
- $10,971
- Net income (line 11)
- -$10,971
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 0
- Expenditures and investments (line 3c)
- $404,800
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| East Asia and the Pacific - Australia, Brunei, Burma, Cambodia, | 0 | 0 | Research grants to recipients in the region | Research Grants | $50,000 |
| Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium | 0 | 0 | Research grants to recipients in the region | Research Grants | $285,000 |
| North America - Canada and Mexico, but not the United States | 0 | 0 | Research grants to recipients in the region | Research Grants | $69,800 |
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| North America - Canada and Mexico, but not the United States | $19,800 | Transfer | $0 | — | — |
| North America - Canada and Mexico, but not the United States | $50,000 | Transfer | $0 | — | — |
| Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium | $50,000 | Transfer | $0 | — | — |
| Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium | $100,000 | Transfer | $0 | — | — |
| Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium | $35,000 | Transfer | $0 | — | — |
| Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium | $50,000 | Transfer | $0 | — | — |
| East Asia and the Pacific | $50,000 | Transfer | $0 | — | — |
| Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium | $50,000 | Transfer | $0 | — | — |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- 8
- Other grantees (Part II line 3)
- 0
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Provenance
- Return type
- form_990
- Tax year
- 2023
- Filed
- 26 April 2024
- IRS schema version
- 2023v5.0
- Source object
- 202431239349301653
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.